Jefferies lowers target price on Life Science REIT
Jefferies cut its price target on real estate investment trust Life Sciences REIT from 45.0p to 36.0p following a visit to the group's Cambourne Science & Technology Park.
Jefferies said it had chosen to lower its earnings estimates on delayed option to purchase leasing due to political and economic uncertainty from FY24 into FY25, which was a timing issue.
However, Jefferies expects an under-supplied market of high-quality lab space to put upward pressure on rents, with the UK increasingly the "centre of excellence" for European Life Science businesses.
"We capitalise the FY25e covered dividend per share (1.80p) at 5% which gives a 36.0p price target (45.0p) with the divi subsidised out of net asset value and anticipating full cover in FY26," added Jefferies, which reiterated its 'hold' rating on the stock.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.